Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Margaret J. Evans is active.

Publication


Featured researches published by Margaret J. Evans.


Clinical Biochemistry | 2001

Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones

Margaret J. Evans; John H. Livesey; M. Jane Ellis; Timothy G. Yandle

OBJECTIVES To determine the effect of different anticoagulants and storage conditions on the stability of hormones in plasma and serum. DESIGN AND METHODS Human blood samples were collected from volunteers into EDTA, lithium heparin, sodium fluoride/potassium oxalate, or tubes without anticoagulant, plasma and serum left at -20 degrees C, 4 degrees C or 30 degrees C for 24 and 120 hours then assayed for ACTH, aldosterone, alpha-subunit, AVP, CRH, C-peptide, estradiol, FSH, glucagon, GH, IGF-1, IGFBP-3, insulin, leptin, LH, PPP, PTH, prolactin and VIP, or at room temperature for 0 to 72 hours (BNP, NT-BNP)(n = 6 per condition). RESULTS The anticoagulant altered the measured concentrations for 9 hormones when compared to EDTA. All hormones except ACTH were stable for > 120 hours in EDTA or fluoride at 4 degrees C, but only 13 hormones were stable in all anticoagulants. At 30 degrees C, 8 hormones were stable for > 120 hours in EDTA, and 3 hormones in all anticoagulants. BNP and NT-BNP were stable for < 24 hours when stored in EDTA or heparin at room temperature. DISCUSSION Storage of samples in EDTA plasma at 4 degrees C is suitable for most hormones (except ACTH) for up to 120 hours.


Clinical Biochemistry | 2003

Hormone stability in human whole blood

M. Jane Ellis; John H. Livesey; Margaret J. Evans

OBJECTIVE To determine whether significant changes in the plasma concentrations of 17 hormones occur when human whole blood is held at 4 or 24 degrees C for up to 24 h before separation of the plasma fraction. DESIGN AND METHODS Blood samples (EDTA) from healthy human volunteers were held at 4 degrees C or 24 degrees C for 0.5, 6 or 24 h before separation. Plasma concentrations of ACTH, aldosterone, gonadotrophin alpha-subunits, AVP, C-peptide, estradiol, FSH, GH, glucagon, IGF-1, IGFBP3, insulin, leptin, LH, prolactin, PTH and VIP were measured and the results compared to baseline values. Nonlinear regression was used to test for a significant mean rate of change. The time interval for median concentrations to change by 10% was determined. RESULTS Significant changes were observed for ACTH (decrease at 18.6 hr, 4 degrees C; 17.5 hr, 24 degrees C); AVP (increase at 2.6 h, 24 degrees C); insulin (decrease at 16.8 hr, 4 degrees C; 16.9 hr, 24 degrees C) and VIP (increase at 18.6 h, 24 degrees C). No changes were detected for the remaining analytes.B CONCLUSIONS: The measurement of some hormones is compromised by a delay in plasma separation from normal human blood. While many hormones appear stable in normal whole blood, we recommend that processing occurs without delay.


Peptides | 1991

Structure of equine corticotropin releasing factor

John H. Livesey; Alan Carne; Clifford H.G. Irvine; Jane Ellis; Margaret J. Evans; Roger Smith; R. A. Donald

A 41 amino acid peptide, probably identical in structure to human corticotropin releasing factor, was isolated from 70 equine hypothalami by methanol extraction, immunoaffinity chromatography and single step of reverse phase HPLC. The amino acid sequence was determined by gas phase sequence analysis. Probable carboxyl terminal amidation was demonstrated by similar retention times for equine and human corticotropin releasing factor on reverse phase HPLC at pH 8. The likely structure of equine corticotropin releasing factor is: Ser-Glu-Glu-Pro-Pro- Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Ala-Arg- Ala-Glu - Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Met-Glu-Ile-Ile-NH2. The purified peptide is equipotent with human corticotropin releasing factor in an in vitro bioassay and in a human plasma binding protein assay.


Animal Reproduction Science | 2002

Effectiveness of an antagonist to gonadotrophin releasing hormone on the FSH and LH response to GnRH in perifused equine pituitary cells, and in seasonally acyclic mares

Margaret J. Evans; Niere E. Kitson; Susan L. Alexander; Clifford H.G. Irvine; Julie E Turner; Nr Perkins; John H. Livesey

We wish to use a gonadotrophin-releasing hormone (GnRH) antagonist in the mare as a tool for investigating the control of the oestrous cycle. The aim of this study was to test the effectiveness of the antagonist cetrorelix by testing both in vitro, using perifused equine anterior pituitary cells, and in vivo in seasonally acyclic mares. Pituitary cells were prepared and after 3-4 days incubation, loaded onto columns and given four pulses of GnRH (at 0, 30, 60 and 90 min; dose-response study). After the second GnRH pulse, infusion of cetrorelix began (0, 100, 1000 and 2000 pmol/l) and continued until the end of the experiment. To mimic luteal phase conditions, cells were pre-incubated and perifused with progesterone (25 nmol/l) and GnRH pulses given at 0, 90, 180 and 270 min. Cetrorelix (0 or 1000 pmol/l) began after the second GnRH pulse. Follicle stimulating hormone (FSH) and luteinizing hormone (LH) concentrations were measured in 5 min fractions. Both FSH and LH response areas (above baseline) after GnRH were inhibited by 1000 pmol/l cetrorelix (P < 0.01, P < 0.01, respectively) but not by 100 pmol/l cetrorelix. Similarly, in the presence of progesterone, cetrorelix inhibited the FSH (P < 0.001) and LH (P = 0.0002) response area. Seasonally acyclic mares, pre-treated for 3 days with progesterone (150 mg i.m. per day) were given cetrorelix as (i) a loading dose of 1 microg/kg then infusion at 2.2 ng/(kg min) for 90 min, (ii) a s.c. injection at 20 microg/kg, (iii) infusion at 2.2 ng/(kg min) for 48 h, and (iv) no cetrorelix (control mares). At 90 min, 6, 24 and 48 h after cetrorelix was first administered, mares were given a bolus injection of GnRH (22.2 ng/kg i.v.) and the FSH and LH responses measured. All doses of cetrorelix inhibited the FSH response at 90 min. The response was no longer suppressed at 6 h in the 90 min infusion group, showing a rapid recovery from inhibition. At 24 h, the FSH responses in the injected and 48 h infusion group were suppressed. The LH concentrations were low and showed no significant changes. This study has defined the time course and dose of cetrorelix with respect to its effect on FSH in the horse. It is concluded that cetrorelix could be used to elucidate the role of FSH in follicular development in cyclic mares.


Neuroendocrinology | 1997

Atrial natriuretic peptide and C-type natriuretic peptide do not acutely inhibit the release of adrenocorticotropin from equine pituitary cells in vitro.

R. Mulligan; John H. Livesey; Margaret J. Evans; M. J. Ellis; R. A. Donald

It has been suggested that atrial natriuretic peptide (ANP) is the long-sought inhibitor of corticotropin (ACTH) secretion, but the evidence is conflicting. We have examined the effect of ANP and C-type natriuretic peptide (CNP) on the secretion of ACTH by perifused equine pituitary cells in an in vitro milieu intended to mimic the in vivo milieu in the horse. Corticotropin-releasing hormone (20 pM) and cortisol (0 or 100 nM) were perifused continuously and 7 pulses of arginine vasopressin (AVP; 10 nM) applied for 5 min at 30-min intervals. ANP (1 nM) or CNP (1 nM) were perifused continuously for 75 min, beginning before the 3rd AVP pulse. Neither ANP nor CNP, with or without cortisol, significantly altered the ACTH secretory response to the AVP pulses. We conclude that these natriuretic peptides are unlikely to act at the pituitary as rapid inhibitors of ACTH secretion in the horse.


Animal Reproduction Science | 2011

Administration of a gonadotropin-releasing hormone antagonist to mares at different times during the luteal phase of the estrous cycle

Margaret J. Evans; Susan L. Alexander; Clifford H.G. Irvine; Niere E. Kitson; T. Bruce Taylor

The GnRH antagonist cetrorelix was given during the early (Days 1-5), mid (Days 6-10 or 5-12) or for the entire (Days 1-16) luteal phase of mares to inhibit the secretion of FSH and LH (Day 0=ovulation). Frequent blood sampling from Day 6 to Day 14 was used to determine the precise time-course of the suppression (cetrorelix given Days 6-10). Cetrorelix treatment caused a decrease in FSH and LH concentrations by 8 and 16 h, respectively, and an obliteration of the response to exogenous GnRH given 24h after treatment onset. Treatment never suppressed gonadotropin concentrations to undetectable levels; e.g. frequent sampling showed that the nadirs reached in FSH and LH were 46.2±6% and 33.1±11%, respectively, of pre-treatment concentrations. Daily FSH concentrations were decreased in all treatment groups but daily LH concentrations were lower only when treatment commenced at the beginning of the luteal phase; progesterone concentrations depended on the time of cetrorelix administration, but the changes suggested a role for LH in corpus luteum function. The inter-ovulatory interval was longer than controls when cetrorelix was given in the mid- or for the entire luteal phase, but was unaffected by treatment in the early phase. Nevertheless, in all groups, FSH concentrations were higher (P<0.05 when compared to Day 0, subsequent ovulation) approximately 6-10 days before this next ovulation. This consistent relationship suggests a stringent requirement for a GnRH-induced elevation of FSH above a threshold at, but only at, this time; i.e. approximately 6-10 days before ovulation.


Journal of Immunoassay & Immunochemistry | 2003

Estimation of Lot-to-Lot Relative Potency in the Preparation of Radioimmunoassay Calibrators

John H. Livesey; Timothy G. Yandle; Margaret J. Evans; M. Jane Ellis

Abstract The aim of this study was to determine guidelines for estimating lot-to-lot differences in the potency of calibrator materials or batches of standards for radioimmunoassays. Thirty one lots of standards for thirteen different analytes were compared to the previous lot for that analyte with the relative potency computed by nine different methods. Assays were performed manually. The nine different calculation methods included non-simultaneous fitting of pairs of standard curves, full or partial simultaneous fitting, and least squares or robust minimisation. The simultaneous methods were found superior to the non-simultaneous in minimising the variance of the relative potency estimates, while robust fitting procedures did not result in a lower variance than least-squares minimisation. The root mean square coefficient of variation for the simultaneous estimation of the relative potency by least squares was 6.1%. On this basis, it is recommended that relative potency estimations in radioimmunoassay be based on at least eight independent pair-wise standard curve comparisons. Additional guidelines for preparing and comparing batches of standards are also given.


Journal of Equine Veterinary Science | 2017

Preovulatory Follicle Dynamics, and Ovulatory and Endometrial Responses to Different Doses of hCG and Prediction of Ovulation in Mares

Shuji P. Tazawa; M.O. Gastal; Luciano Andrade Silva; Margaret J. Evans; E.L. Gastal

ABSTRACT A more precise characterization of the effects of human chorionic gonadotropin (hCG) treatment on the preovulatory follicle is needed to improve reproductive efficiency in broodmare management. The objectives of this study were (1) to study the effects of different hCG doses within and among three consecutive estrous cycles on ovulatory response, preovulatory follicle dynamics, and endometrial echotexture; (2) to study the temporal relationship among changes in preovulatory follicle diameter, endometrial echotexture, and estradiol levels; and (3) to analyze a system for prediction of ovulation. In experiment 1, mares were treated with 2,500 IU hCG, 1,500 IU hCG, 500 IU hCG, or saline (controls) and examined by ultrasonography every 6 hours across three consecutive preovulatory periods (n = 135). Similar treatment groups were utilized in experiment 2 (n = 177 preovulatory periods) with examinations performed every six, 12, or 24 hours to test the effectiveness of a prediction of ovulation system. Effective hCG doses (2,500 and 1,500 IU) led to cessation of growth rate and reduction of the preovulatory follicle diameter concurrently with a reduction in systemic estradiol concentration and endometrial echotexture score. A system of prediction of ovulation, based on preovulatory follicle ultrasonographic signs of impending ovulation, was highly accurate for the diagnosis of positive and negative outcomes in both hCG‐treated and control groups. However, the effectiveness of this prediction system was reduced due to the false‐negative diagnoses that were a reflection of a lack of sensitivity for the detection of nonovulation. HIGHLIGHTSEffects of different human chorionic gonadotropin (hCG) doses on three consecutive estrous cycles.Follicle dynamics, estradiol, and ovulatory and endometrial responses were evaluated.A prediction of ovulation system was developed.Effective hCG doses reduced growth rate of the preovulatory follicle and estradiol concentration and endometrial echotexture score.The developed system of prediction of ovulation was highly accurate.


The Clinical biochemist. Reviews / Australian Association of Clinical Biochemists | 2008

Pre-Analytical Requirements

John H. Livesey; M. Jane Ellis; Margaret J. Evans


Endocrine Research | 2000

Interactions of CRH, AVP and Cortisol in the Secretion of ACTH From Perifused Equine Anterior Pituitary Cells: "Permissive" Roles for Cortisol and CRH

John H. Livesey; Margaret J. Evans; R. Mulligan; R. A. Donald

Collaboration


Dive into the Margaret J. Evans's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Susan L. Alexander

Lincoln University (Pennsylvania)

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

E.L. Gastal

Southern Illinois University Carbondale

View shared research outputs
Top Co-Authors

Avatar

M.O. Gastal

Southern Illinois University Carbondale

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge